More Syntara Limited news
Syntara LimitedASX: SNT

PXS to Receive Stg2.9m from Parkinsons UK for New Trial

Aug 31, 2022 at 10:46 PM EDT · Issued by Syntara Limited

Filed with ASX · Aug 31, 2022 at 10:46 PM EDT · 4 pages · English

On 6ix: 6ix.com/news/pxs-to-receive-stg2.9m-from-parkinsons-uk-for-new-trial

Syntara Limited has released a press release.

View Attachment

6ix is checking which company filed this.

Syntara Limited on 6ix

Story so far

  • PXS Collaborators Receive Government Grants of $1.4mJan 6, 2022
  • PXS Doses First Patient in Phase 2 Bone Marrow Cancer TrialOct 13, 2021
  • PXS Cleared to Progress to Phase 2 Bone Marrow Cancer TrialOct 5, 2021

Earlier from Syntara

  • Aptar Pharma Pays PXS Us$5m to Acquire Orbital TechnologyAug 4, 2022
  • Clarification AnnouncementMay 13, 2022
  • Appendix 4C Quarterly Cash Flow ReportApr 28, 2022
  • Response to ASX Aware QueryJan 10, 2022
  • PXS Collaborators Receive Government Grants of $1.4mJan 5, 2022

Later from Syntara

  • PXS Releases Promising Interim Data from Skin Scarring StudySep 25, 2022
  • Investor PresentationOct 18, 2022
  • PXS announces positive interim data from myelofibrosis trialOct 18, 2022
  • After FDA Review PXS Accelerates Plans for Combination StudyApr 11, 2023
  • PXS Announces Encouraging Results from Phase 1c Scar StudyMay 23, 2023
All Syntara news releases↗

Follow Syntara into a list and get an email when it puts out news.

Follow Syntara
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer